Clinical features and molecular genetics of autosomal recessive cerebellar ataxias

Lancet Neurology

Volumn 6, Issue 3, 2007, Pages 245-257

  Fogel, Brent L ^a   Perlman, Susan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOSOMAL RECESSIVE DISORDER; CELL METABOLISM; CEREBELLAR ATAXIA; CLINICAL FEATURE; COGNITIVE DEFECT; DIFFERENTIAL DIAGNOSIS; DNA REPAIR; EYE DISEASE; HUMAN; INVOLUNTARY MOVEMENT; MITOCHONDRIAL RESPIRATION; MOLECULAR GENETICS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA PROCESSING; SEIZURE; SENSORIMOTOR NEUROPATHY; SKELETON MALFORMATION; SKIN DISEASE; SPINOCEREBELLAR DEGENERATION;

ABETALIPOPROTEINEMIA; ATROPHY; CEREBELLAR ATAXIA; CEREBELLUM; FRIEDREICH ATAXIA; GENES, RECESSIVE; HUMANS; PHENOTYPE; VITAMIN E DEFICIENCY;

EID: 33846882183     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70054-6     Document Type: Review

References (129)

1. Harding A. Classification of the hereditary ataxias and paraplegias. Lancet 1 (1983) 1151-1155
2. Perlman S. Symptomatic and disease-modifying therapy for the progressive ataxias. Neurologist 10 (2004) 275-289
3. Schols L., Bauer P., Schmidt T., Schulte T., and Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 3 (2004) 291-304
4. Di Donato S., Gellera C., and Mariotti C. The complex clinical and genetic classification of inherited ataxias-II: autosomal recessive ataxias. Neurol Sci 22 (2001) 219-228
5. van de Warrenburg B., Sinke R., and Kremer B. Recent advances in hereditary spinocerebellar ataxias. J Neuropathol Exp Neurol 64 (2005) 171-180
6. Harding A. Early onset cerebellar ataxia with retained tendon reflexes: a clinical and genetic study of a disorder distinct from Friedreich's ataxia. J Neurol Neurosurg Psychiatry 44 (1981) 503-508
7. Pandolfo M. Molecular pathogenesis of Friedreich ataxia. Arch Neurol 56 (1999) 1201-1208
8. Pandolfo M. Molecular basis of Friedreich ataxia. Mov Disord 16 (2001) 815-821
9. Cossee M., Schmitt M., Campuzano V., et al. Evolution of the Friedreich's ataxia trinucleotide repeat expansion: Founder effect and premutations. Proc Natl Acad Sci USA 94 (1997) 7452-7457
10. Schols L., Amoiridis G., Przuntek H., Frank G., Epplen J., and Epplen C. Friedreich's ataxia. Brain 120 (1997) 2131-2140
11. Alper G., and Narayanan V. Friedreich's ataxia. Pediatr Neurol 28 (2003) 335-341
12. Harding A. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104 (1981) 589-620
13. Delatycki M., Williamson R., and Forrest S. Friedreich ataxia: an overview. J Med Genet 37 (2000) 1-8
14. Voncken M., Ioannou P., and Delatycki M. Friedreich ataxia-update on pathogenesis and possible therapies. Neurogenetics 5 (2004) 1-8
15. Lynch D., Farmer J., Balcer L., and Wilson R. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 59 (2002) 743-747
16. Bhidayasiri R., Perlman S., Pulst S., and Geschwind D. Late-onset Friedreich ataxia 62 (2005) 1865-1869
17. Campuzano V., Montermini L., Molto M., Pianese L., et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271 (1996) 1423-1427
18. Bidichandani S., Ashizawa T., and Patel P. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet 62 (1998) 111-121
19. Grabczyk E., and Usdin K. The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res 28 (2000) 2815-2822
20. Patel P., and Isaya G. Friedreich ataxia: from GAA triplet-repeat expansion to frataxin deficiency. Am J Hum Genet 69 (2001) 15-24
21. Sakamoto N., Chastain P., Parniewski P., et al. Sticky DNA: Self-association properties of long GAA*TTC repeats in R*R*Y triplex structures from Friedreich's ataxia. Mol Cell 3 (1999) 465-475
22. Mateo I., Llorca J., Volpini V., Corral J., Berciano J., and Combarros O. GAA expansion size and age at onset of Friedreich's ataxia. Neurology 61 (2003) 274-275
23. Puccio H., and Koenig M. Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum Mol Genet 9 (2000) 887-892
24. Montermini L., Richter A., Morgan K., et al. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol 41 (1997) 675-682
25. Hellenbroich Y., Schwinger E., and Zuhlke C. Limited somatic mosaicism for Friedreich's ataxia GAA triplet repeat expansions identified by small pool PCR in blood leukocytes. Acta Neurol Scand 103 (2001) 188-192
26. Campuzano V., Montermini L., Lutz Y., et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 6 (1997) 1771-1780
27. Bradley J., Blake J., Chamberlain S., Thomas P., Cooper J., and Schapira A. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet 9 (2000) 275-282
28. Cavadini P., O'Neill H., Benada O., and Isaya G. Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia. Hum Mol Genet 11 (2002) 217-227
29. Lodi R., Copper J., Bradley J., et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci USA 96 (1999) 11492-11495
30. Babcock M., de Silva D., Oaks R., et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276 (1997) 1709-1712
31. Gakh O., Park S., Liu G., et al. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum Mol Genet 15 (2006) 467-479
32. Cavadini P., Gellera C., Patel P., and Isaya G. Human frataxin maintains mitochondrial iron homeostasis in Saccharomyces cerevisiae. Hum Mol Genet 9 (2000) 2523-2530
33. Cossee M., Puccio H., Gansmuller A., et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 9 (2000) 1219-1226
34. Pook M., Al-Mahdawi S., Carroll C., et al. Rescue of the Friedreich's ataxia knockout mouse by human YAC transgenesis. Neurogenetics 3 (2001) 185-193
35. Puccio H., Simon D., Cossee M., et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27 (2001) 181-186
36. Wilson R. Frataxin and frataxin deficiency in Friedreich's ataxia. J Neurol Sci 207 (2003) 103-105
37. Durr A. Friedreich's ataxia: treatment within reach. Lancet Neurol 1 (2002) 370-374
38. Hart P., Lodi R., Rajagopalan B., et al. Antioxidant treatment of patients with Friedreich ataxia. Arch Neurol 62 (2005) 621-626
39. Buyse G., Mertens L., Di Salvo G., et al. Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology 60 (2003) 1679-1681
40. Hausse A., Aggoun Y., Bonnet D., et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87 (2002) 346-349
41. Mariotti C., Solari A., Torta D., Marano L., Fiorentini C., and Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60 (2003) 1676-1679
42. Rustin P., von Kleist-Retzow J., Chantrel-Groussard K., Sidi D., Munnich A., and Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 354 (1999) 477-479
43. Seznec H., Simon D., Monassier L., et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet 13 (2004) 1017-1024
44. Benomar A., Yahyaoui M., Meggouh F., et al. Clinical comparison between AVED patients with 744 del A mutation and Friedreich ataxia with GAA expansion in 15 Moroccan families. J Neurol Sci 198 (2002) 25-29
45. Cavalier L., Ouahchi K., Katden H., et al. Ataxia with isolated vitamin E deficiency: heterogeneity of mutations and phenotypic variability in a large number of families. Am J Hum Genet 62 (1998) 301-310
46. Marzouki N., Benomar A., Yahyaoui M., et al. Vitamin E deficiency ataxia with (744 del A) mutation on α-TTP gene: genetic and clinical peculiarities in Moroccan patients. Eur J Med Genet 48 (2005) 21-28
47. Ben Hamida C., Doerflinger N., Belal S., et al. Localization of Friedreich ataxia phenotype with selective vitamin E deficiency to chromosome 8q by homozygosity mapping. Nat Genet 5 (1996) 195-200
48. Ouahchi K., Arita M., Kayden H., et al. Ataxia with isolated vitamin E deficiency is caused by mutations in the α-tocopherol transfer protein. Nat Genet 9 (1995) 141-145
49. Copp R., Wisniewski T., Hentati F., Larnaout A., Ben Hamida M., and Kayden H. Localization of α-tocopherol transfer protein in the brains of patients with ataxia with vitamin E deficiency and other oxidative stress related neurodegenerative disorders. Brain Res 822 (1999) 80-87
50. Gabsi S., Gouider-Khouja N., Belal S., et al. Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency. Eur J Neurol 8 (2001) 477-481
51. Yokota T., Igarashi K., Uchihara T., et al. Delayed-onset ataxia in mice lacking alpha-tocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress. Proc Natl Acad Sci USA 98 (2001) 15185-15190
52. Narcisi T., Shoulders C., Chester S., et al. Mutations of the microsomal triglyceride-transfer-protein in abetalipoproteinemia. Am J Hum Genet 57 (1995) 1298-1310
53. Wang J., and Hegele R. Microsomal triglyceride transfer protein (MTP) gene mutations in canadian subjects with abetalipoproteinemia. Hum Mutat 15 (2000) 294-295
54. Berriot-Varoqueaux N., Aggerbeck L., Samson-Bouma M.-E., and Wetterau J. The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Annu Rev Nutr 20 (2000) 663-697
55. Chang B., Liao W., Li L., Nakamuta M., Mack D., and Chan L. Liver-specific inactivation of the abetalipoproteinemia gene completely abrogates very low density lipoprotein/low density lipoprotein production in a viable conditional knockout mouse. J Biol Chem 274 (1999) 6051-6055
56. Jansen G., Waterham H., and Wanders R. Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7). Hum Mutat 23 (2004) 209-218
57. Wills A., Manning N., and Reilly M. Refsum's disease. Q J Med 94 (2001) 403-406
58. Weinstein R. Phytanic acid storage disease (Refsum's disease): clinical characteristics, pathophysiology and the role of therapeutic apheresis in its management. J Clin Apher 14 (1999) 181-184
59. van den Brink D., Brites P., Haasjes J., et al. Identification of PEX7 as the second gene involved in Refsum disease. Am J Hum Genet 72 (2003) 471-477
60. Schon E., Santra S., Pallotti F., and Girvin M. Pathogenesis of primary defects in mitochondrial ATP synthesis. Semin Cell Dev Biol 12 (2001) 441-448
61. Eklund E., and Freeze H. The congenital disorders of glycoslyation: a multifaceted group of syndromes. NeuroRx 3 (2006) 254-263
62. Jeyakumar M., Butters T., Dwek R., and Platt F. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol Appl Neurobio 28 (2002) 343-357
63. Montalvo A., Filocamo M., Vlahovicek K., et al. Molecular analysis of the HEXA gene in Italian patients with infantile and late onset Tay-Sachs disease: detection of fourteen novel alleles. Hum Mutat 26 (2005) 2-8
64. Neudorfer O., Pastores G., Zeng B., Gianutsos J., Zarodd C., and Kolodny E. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med 7 (2005) 119-123
65. Miklyaeva E., Dong W., Bureau A., et al. Late onset Tay-Sachs disease in mice with targeted disruption of the Hexa gene: behavioral changes and pathology of the central nervous system. Brain Res 1001 (2004) 37-50
66. Jeyakumar M., Smith D., Eliot-Smith E., et al. An inducible mouse model of late onset Tay-Sachs disease. Neurobiol Dis 10 (2002) 201-210
67. Jeyakumar M., Thomas R., Elliot-Smith E., et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126 (2003) 974-987
68. Aerts J., Hollak C., Boot R., Groener J., and Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis 29 (2006) 449-456
69. Cachon-Gonzalez M., Wang S., Lynch A., Ziegler R., Cheng S., and Cox T. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc Natl Acad Sci USA 103 (2006) 10373-10378
70. Lorincz M., Rainier S., Thomas D., and Fink J. Cerebrotendinous xanthomatosis. possible higher prevalence than previously recognized. Arch Neurol 62 (2005) 1459-1463
71. Moghadasian M., Salen G., Frohlich J., and Scudamore C. Cerebrotendinous xanthomatosis. a rare disease with diverse manifestations. Arch Neurol 59 (2002) 527-529
72. Verrips A., Hoefsloot L., Steenbergen G., et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 123 (2000) 908-919
73. Longley M., Graziewica M., Bienstock R., and Copeland W. Consequences of mutations in human DNA polymerase γ. Gene 354 (2005) 125-131
74. Horvath R., Hudson G., Ferrari G., et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase γ gene. Brain 129 (2006) 1674-1684
75. Van Goethem G., Luoma P., Rantamaki M., et al. POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement. Neurology 63 (2004) 1251-1257
76. Van Goethem G., Martin J., Dermaut B., et al. Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. Neuromuscul Disord 13 (2003) 133-142
77. Winterthun S., Ferrari G., He L., et al. Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase γ mutations. Neurology 64 (2005) 1204-1208
78. Rantamaki M., Krahe R., Paetau A., Cormand B., Mononen I., and Udd B. Adult-onset autosomal recessive ataxia with thalamic lesions in a Finnish family. Neurology 57 (2001) 1043-1049
79. Hakonen A., Heiskanen S., Juvonen V., et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet 77 (2005) 430-441
80. Tzoulis C., Engelsen B., Telstad W., et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 129 (2006) 1685-1692
81. Takashima H., Boerkoel C., John J., et al. Mutation of TDP1, encoding a topoisomerase I-dependant DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet 32 (2002) 267-272
82. El-Khamisy S., Saifi G., Weinfeld M., et al. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 434 (2005) 108-113
83. El-Khamisy S., and Caldecott K. TDP1-dependant DNA single-strand break repair and neurodegeneration. Mutagenesis 21 (2006) 219-224
84. Filla A., De Michele G., Cavalcanti F., et al. Clinical and genetic heterogeneity in early onset cerebellar ataxia with retained tendon reflexes. J Neurol Neurosurg Psychiatry 53 (1990) 667-670
85. Ball L., and Xiao W. Molecular basis of ataxia telangiectasia and related diseases. Acta Pharmacologica Sinica 26 (2005) 897-907
86. Taylor A., and Byrd P. Molecular pathology of ataxia telangiectasia. J Clin Pathol 58 (2005) 1009-1015
87. McKinnon P. ATM and ataxia telangiectasia. EMBO Rep 5 (2004) 772-776
88. Chun H., and Gatti R. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 3 (2004) 1187-1196
89. Savitsky K., Bar-Shira A., Gilad S., et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268 (1995) 1749-1753
90. Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 31 (2006) 402-410
91. Lee J., and Lim D. Dual role of Nbs1 in the ataxia telangiectasia mutated-dependent DNA damage response. FEBS J 273 (2006) 1630-1636
92. Taylor A., Groom A., and Byrd P. Ataxia-telangiectasia-like disorder (ATLD) - its clinical presentation and molecular basis. DNA Repair (Amst) 3 (2004) 1219-1225
93. Frappart P., Tong W., Demuth I., et al. An essential function for NBS1 in the prevention of ataxia and cerebellar defects. Nat Med 11 (2005) 484-490
94. Barlow C., Hirotsune S., Paylor R., et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86 (1996) 159-171
95. Xu Y., Ashley T., Brainerd E., Bronson R., Meyn M., and Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev 10 (1996) 2411-2422
96. Moreira M., Barbot C., Tachi N., et al. The gene mutated in ataxia-ocular apraxia 1 encodes the HIT/Zn-finger protein aprataxin. Nat Genet 29 (2001) 189-193
97. Date H., Onodera O., Tanaka H., et al. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. Nat Genet 29 (2001) 184-188
98. Criscuolo C., Mancini P., Sacca F., et al. Ataxia with oculomotor apraxia type 1 in southern Italy: late onset and variable phenotype. Neurology 63 (2004) 2173-2175
99. Amouri R., Moreira M., Zouari M., et al. Aprataxin gene mutations in Tunisian families. Neurology 63 (2004) 928-929
100. Le Ber I., Moreira M., Rivaud-Pechoux S., et al. Cerebellar ataxia with oculomotor apraxia type 1: clinical and genetic studies. Brain 126 (2003) 2761-2772
101. Shimazaki H., Takiyama Y., Sakoe K., et al. Early-onset ataxia with oculomotor apraxia and hypoalbuminemia: the aprataxin gene mutations. Neurology 59 (2002) 590-595
102. Moreira M., Barbot C., Tachi N., et al. Homozygosity mapping of Portuguese and Japanese forms of ataxia-oculomotor apraxia to 9p13, and evidence for genetic heterogeneity. Am J Hum Genet 68 (2001) 501-508
103. Kijas A., Harris J., Harris J., and Lavin M. Aprataxin forms a discrete branch in the HIT (histidine triad) superfamily of proteins with both DNA/RNA bindings and nucleotide hydrolase activities. J Biol Chem 281 (2006) 13939-13948
104. Mosesso P., Piane M., Palitti F., Pepe G., Penna S., and Chessa L. The novel human gene aprataxin is directly involved in DNA single-strand-break repair. Cell Mol Life Sci 62 (2005) 485-491
105. Le Ber I., Bouslam N., Rivaud-Pechoux S., et al. Frequency and phenotypic spectrum of ataxia with oculomotor apraxia 2: a clinical and genetic study in 18 patients. Brain 127 (2004) 759-767
106. Moreira M., Klur S., Watanabe M., et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet 36 (2004) 225-227
107. Duquette A., Roddier K., McNabb-Baltar J., et al. Mutations in senataxin responsible for Quebec cluster of ataxia with neuropathy. Ann Neurol 57 (2005) 408-414
108. Criscuolo C., Chessa L., Di Giandomenico S., et al. Ataxia with oculomotor apraxia type 2: a clinical, pathologic, and genetic study. Neurology 66 (2006) 1207-1210
109. Chen Y., Hashemi S., Anderson S., et al. Senataxin, the yeast Sen1p orthologue: characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neuron disease. Neurobiol Dis 23 (2006) 97-108
110. Ursic D., Chinchilla K., Finkel J., and Culbertson M. Multiple protein/protein and protein/RNA interactions suggest roles for yeast DNA/RNA helicase Sen1p in transcription, transcription-coupled DNA repair, and RNA processing. Nucleic Acids Res 32 (2004) 2441-2452
111. Chen Y., Bennett C., Huynh H., et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 74 (2004) 1128-1135
112. Bouchard J., Richter A., Mathieu J., et al. Autosomal recessive spastic ataxia of Charlevoix-Saguenay. Neuromuscul Disord 8 (1998) 474-479
113. El Euch-Fayache G., Lalani I., Amouri R., et al. Phenotypic features and genetic findings in sacsin-related autosomal recessive ataxia in Tunisia. Arch Neurol 60 (2003) 982-988
114. Mrissa N., Belal S., Ben Hamida C., et al. Linkage to chromosome 13q11-12 of an autosomal recessive cerebellar ataxia in a Tunisian family. Neurology 54 (2000) 1408-1414
115. Richter A., Ozgul R., Poisson V., and Topaloglu H. Private SACS mutations in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) families from Turkey. Neurogenetics 5 (2004) 165-170
116. Engert J., Berube P., Mercier J., et al. ARSACS, a spastic ataxia common in northeastern Quebec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat Genet 24 (2000) 120-125
117. Criscuolo C., Banfi S., Orio M., et al. A novel mutation in SACS gene in a family from southern Italy. Neurology 62 (2004) 100-102
118. Criscuolo C., Sacca F., De Michele G., et al. Novel Mutation of SACS gene in a Spanish family with autosomal recessive spastic ataxia. Mov Disord 20 (2005) 1358-1361
119. Grieco G., Malandrini A., Comanducci G., et al. Novel SACS mutations in autosomal recessive spastic ataxia of Charlevoix-Saguenay type. Neurology 62 (2004) 103-106
120. Ogawa T., Takiyama Y., Sakoe K., et al. Identification of a SACS gene missense mutation in ARSACS. Neurology 62 (2004) 107-109
121. Hara K., Onodera O., Endo M., et al. Sacsin-related autosomal recessive ataxia without prominent retinal myelinated fibers in Japan. Mov Disord 20 (2005) 380-382
122. Nikali K., Suomalainen A., Saharinen J., et al. Infantile onset spinocerebellar ataxia is caused by recessive mutations in mitochondrial proteins twinkle and twinky. Hum Mol Genet 14 (2005) 2981-2990
123. Lonnqvist T., Paetau A., Nikali K., von Boguslawski K., and Pihko H. Infantile onset spinocerebellar ataxia with sensory neuropathy (IOSCA): neuropathological features. J Neurol Sci 161 (1998) 57-65
124. Nystuen A., Benke P., Merren J., Stone E., and Sheffield V. A cerebellar ataxia locus identified by DNA pooling to search for linkage disequilibrium in an isolated population from the Cayman Islands. Hum Mol Genet 5 (1996) 525-531
125. Bomar J., Benke P., Slattery E., et al. Mutations in a novel gene encoding a CRAL-TRIO domain cause human Cayman ataxia and ataxia/dystonia in the jittery mouse. Nat Genet 35 (2003) 264-269
126. Buschdorf J., Chew L., Zhang B., et al. Brain-specific BNIP-2-homology protein Caytaxin relocalizes glutaminase to neurite terminals and reduces glutamate levels. J Cell Sci 119 (2006) 3337-3350
127. Slavotinek A., Goldman J., Weisiger K., et al. Marinesco-Sjogren syndrome in a male with mild dysmorphism. Am J Med Genet A 133 (2005) 197-201
128. Anttonen A., Mahjneh I., Hamalainen R., et al. The gene disrupted in Marinesco-Sjogren syndrome encodes SIL1, an HSPA5 cochaperone. Nat Genet 37 (2005) 1309-1311
129. Senderek J., Krieger M., Stendel C., et al. Mutations in SIL1 cause Marinesco-Sjogren syndrome, a cerebellar ataxia with cataract and myopathy. Nat Genet 37 (2005) 1312-1314